InvestSMART

ImExHS Limited (ASX:IME)

ALERT: Price-sensitive ASX Announcement for IME
Current share price for IME : $0.325 0 (0%)+
Announcement
Release
31 Jul 2025 12:44PM
Price at Release
$0.325
Full Release
download
Summary
ImExHS Limited (IME) released its Q2 2025 Quarterly Activities Report and Appendix 4C, detailing the company’s ongoing operational, financial, and business developments for the quarter. The report highlights the company’s continued progress in expanding its customer footprint, improving operational efficiencies, and developing new business partnerships. IME continues to focus on the Latin American, US, and Australian markets, reporting solid growth in both recurring revenue and customer acquisitions. The company provides updates on its SaaS-based radiology and medical imaging solutions, notes key contracts secured during the reporting period, and comments on its strategic initiatives aimed at enhancing product development and market reach. Financially, cash receipts from customers increased, while the company maintained a disciplined approach to costs. The report also includes a summary of cash flows for the quarter, providing an outlook for continued growth and strategic initiatives in the upcoming periods.
Key Points
  • ImExHS Limited reported on its quarterly activities and financial results for Q2 2025.
  • The company continues to expand its presence in Latin America, the US, and Australia.
  • Revenue growth is driven by increased SaaS adoption and new customer contracts.
  • Significant progress was made in cost management and operational efficiency.
  • New business partnerships and contracts were secured during the quarter.
  • Product development and strategic initiatives remain a focus to support future growth.
  • Cash receipts from customers increased compared to previous quarters.
  • The financial report includes a summary of cash flows and an outlook for continued growth.
  • The company remains committed to enhancing its radiology and medical imaging solutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.